iBio (NASDAQ:IBIO – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Insider & Institutional Ownership
7.9% of iBio shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares iBio and Legend Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iBio | N/A | -40.66% | -35.78% |
| Legend Biotech | -7.21% | -8.71% | -5.40% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iBio | $100,000.00 | 655.76 | -$33.04 million | ($0.34) | -3.88 |
| Legend Biotech | $1.03 billion | 4.06 | -$296.80 million | ($0.25) | -86.16 |
iBio has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
iBio has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for iBio and Legend Biotech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iBio | 1 | 0 | 4 | 3 | 3.12 |
| Legend Biotech | 1 | 6 | 8 | 0 | 2.47 |
iBio currently has a consensus price target of $5.00, suggesting a potential upside of 278.79%. Legend Biotech has a consensus price target of $53.43, suggesting a potential upside of 148.04%. Given iBio’s stronger consensus rating and higher probable upside, equities analysts plainly believe iBio is more favorable than Legend Biotech.
Summary
iBio beats Legend Biotech on 9 of the 15 factors compared between the two stocks.
About iBio
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
